MAIA MAIA Biotechnology, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1878313 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.4%
TTM EPS YoY36.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-341.5%
ROA-148.3%
ROIC (approx.)-296.5%
Asset turnover—
Leverage & solvency
Liabilities / assets33.6%
Debt / equity0.00x
Current ratio3.41x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio1.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $5.34M | $5.64M | $43,651 | -$12.21M | $6.36M | $3.11M | $3.20M | $2.97M |
| SG&A expense | $2.69M | $2.68M | $3.42M | $2.44M | $3.00M | $2.06M | $2.23M | $2.04M |
| Operating income | -$8.02M | -$8.32M | -$6.95M | -$4.32M | -$9.36M | -$5.17M | -$5.43M | -$5.00M |
| Interest expense | — | — | — | — | — | — | — | -$28 |
| Income tax | — | — | $339 | $2,000 | $0 | $0 | $0 | $2,000 |
| Net income | -$7.18M | -$7.94M | -$6.37M | -$3.63M | -$8.90M | -$5.35M | -$4.52M | -$3.57M |
| EPS (basic) | -0.12 | -0.13 | -0.14 | — | -0.27 | -0.18 | -0.16 | — |
| EPS (diluted) | -0.12 | -0.13 | -0.14 | — | -0.27 | -0.18 | -0.16 | — |
| Weighted avg. shares (diluted) | 60.86M | 60.79M | 45.21M | — | 33.20M | 30.30M | 27.70M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current assets | $22.10M | $28.24M | $35.32M | $9.70M | $11.75M | $11.04M | $11.86M | $10.15M |
| Total assets | $22.10M | $28.24M | $35.32M | $9.70M | $11.78M | $11.05M | $11.86M | $10.16M |
| Current liabilities | $6.47M | $6.26M | $6.32M | $5.84M | $9.99M | $5.04M | $5.06M | $3.83M |
| Total liabilities | $7.43M | $7.57M | $7.56M | $7.33M | $11.74M | $7.17M | $6.92M | $6.52M |
| Shareholders' equity | $14.67M | $20.68M | $27.76M | $2.38M | $41,670 | $3.88M | $4.94M | $3.63M |
| Shares outstanding | 61.74M | 60.82M | 60.67M | 38.62M | 34.45M | 31.82M | 29.59M | 26.16M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.31M | -$6.75M | -$5.31M | -$7.02M | -$3.49M | -$4.14M | -$4.20M | -$3.91M |
| Financing cash flow | $0 | -$65,000 | $31.05M | $4.80M | $4.23M | $3.41M | $5.46M | $4.85M |
| Stock-based compensation | $881,757 | $723,915 | $650,024 | $810,796 | $646,900 | $802,484 | $371,472 | $693,443 |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.